Dr. Lawrence Herman, DMSc, MPA, PA-C, DFAAPA
Obesity affects 100 million people in the United States and has an aggregate cost of $100 billion annually.1 Obesity is directly implicated in increased rates of Type 2 diabetes, hypertension, heart disease, strokes, gallbladder disease, fatty liver, sleep apnea, arthritis, and certain types of cancers. Over 300,000 deaths are linked to obesity each year in the US. With limited treatment options, lack of anti-obesity medications, and high relapse rates, chronic obesity continues to be problematic. A new treatment option, semaglutide 2.4 mg subcutaneously once-weekly, has been approved by the FDA for obesity management in adjunct to decreased caloric intake and increased energy expenditure. Responsible prescribing of once-weekly subcutaneous semaglutide 2.4 mg will provide patients with a superior option for weight loss over placebo.
Walton SM. Semaglutide 2.4 mg Subcutaneously Once-Weekly for Weight Reduction. Lynchburg Journal of Medical Science. 2022; 4(2).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.